Cantel Medical

Cantel Medical Corp. (NYSE:CMN) is a leading provider of infection prevention and control products in the healthcare market. Their products include water purification equipment, sterilants, disinfectants and cleaners, specialized medical device reprocessing systems for endoscopy and renal dialysis, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates and other dialysis supplies, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. They also provide technical maintenance for their products and offer compliance training services for the transport of infectious and biological specimens.

Cantel Medical Corp. engages in the development and manufacture of infection prevention products and services in the healthcare market. It operates through the following business segments: Medical, Life Sciences, Dental and Dialysis. The Medical segment designs, develops, manufactures, sells and installs a comprehensive products and services comprising a complete circle of infection prevention solutions. The Life Sciences segment designs, develops, manufactures, sells and installs water purification systems for medical, pharmaceutical and other bacteria controlled applications. The Dental segment designs, manufactures, sells, supplies and distributes single-use infection prevention healthcare products, used by dental practitioners. The Dialysis segment designs, develops, manufactures, and sells reprocessing systems for dialyzers. Cantel Medical was founded on August 16, 1963 and is headquartered in Little Falls, NJ.

Baidu

Trinseo PLC

Top Ranked Momentum Stocks to Buy for December 23rd

Evercore

Rio Tinto plc Sponsored

Top Ranked Momentum Stocks to Buy for December 21st

Cantel (CMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Cantel (CMD) Upgraded to Strong Buy: Here's What You Should Know

Cantel Medical Corp. (CMD) CEO George Fotiades on Q1 2021 Results - Earnings Call Transcript

iBio

Sutro Biopharma Inc

iBio (NYSE: IBIO) shares are trading lower on Tuesday after the company announced a common stock offering. iBio's main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates.

Why iBio, Sutro And Cantel Medical Are Moving Today

The company's latest quarterly earnings report managed to impress investors.

Why Cantel Medical Stock Is Soaring Today

Cantel (CMD) delivered earnings and revenue surprises of 150.00% and 1.55%, respectively, for the quarter ended October 2020. Do the numbers hold clues to what lies ahead for the stock?

Cantel Medical (CMD) Q1 Earnings and Revenues Top Estimates

Shares of Cantel Medical (NYSE:CMD) were unchanged in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 38.46% over the past year to $0.90, which beat the estimate of $0.37.

Cantel Medical: Q1 Earnings Insights

LITTLE FALLS, N.J., Dec. 8, 2020 /PRNewswire/ -- Cantel Medical Corp. (NYSE: CMD) today announced financial results for its first quarter ended October 31, 2020. First quarter 2021 net sales were $297.0M, up 15.5% compared to the prior year. Excluding the impact from foreign currency, net...

Cantel Medical Reports Financial Results for its First Quarter Fiscal Year 2021

LITTLE FALLS, N.J., Dec. 7, 2020 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE:CMD) and Censis Technologies announced today a new long-term partnership to combine Cantel's leading infection prevention endoscope reprocessing workflow portfolio with the surgical asset management and instrument...

Cantel Medical and Censis Technologies Enter into Partnership to Develop Differentiated Endoscope Reprocessing Software Solution

FRANKLIN, Tenn.--(BUSINESS WIRE)--Today, Censis Technologies, a wholly owned subsidiary of Fortive Corporation, and Cantel Medical Corp announced a new long-term partnership to combine Cantel's leading infection prevention endoscope reprocessing workflow portfolio with the surgical asset management and instrument tracking solutions from Censis. The new enhanced, co-branded software solution will combine the CANEXIS™ Integrated Workflow Solution for Endoscopy from Cantel with Censis' CensiTrac™

Censis Technologies and Cantel Medical Enter Into Partnership to Develop Differentiated Endoscope Reprocessing Software Solution

Cantel (CMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Cantel Medical (CMD) Q1 Earnings Expected to Decline

Cantel Medical has the legs to reach historical growth levels over the coming periods, backed by a strong Q4 performance. Q1 pre-announcements have indicated a stronger than expected sales recovery, and growth cadence has outpaced initial projections.

Cantel Medical: Further Upside Driven By Infection Control Consumables

Cantel (CMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Cantel (CMD) Beat Estimates Again in Its Next Earnings Report?

Johnson & Johnson

STERIS

COVID-19 has heightened the demand for companies that specialize in infection control.

3 Surefire Stocks to Watch In The Coronavirus Pandemic

Clorox

Ecolab

Kimberly-Clark

Neogen

Sonoma Pharmaceuticals

The Covid-19 pandemic has given a significant boost to many industries such as manufacturers of gloves, masks, sanitizers, PPE (personal protective equipment), health insurance providers, and many more related areas.

These Surface Disinfectant Stocks Have Strong Upside Potential

CHICAGO, Oct. 1, 2020 /PRNewswire/ -- HuFriedyGroup, the dental division of Cantel Medical Corp. (NYSE: CMD), and a global leader in infection prevention, dental instrument manufacturing, and instrument reprocessing workflows for the dental market, today introduced the new line of...

HuFriedyGroup Introduces Harmony™ Ergonomic Scaler Designed with TrueFit™ Technology

Cantel Medical Corp. (CMD) CEO George Fotiades on Q4 2020 Results - Earnings Call Transcript

Cantel (CMD) delivered earnings and revenue surprises of 200.00% and 0.14%, respectively, for the quarter ended July 2020. Do the numbers hold clues to what lies ahead for the stock?

Cantel Medical (CMD) Surpasses Q4 Earnings and Revenue Estimates

Shares of Cantel Medical (NYSE:CMD) moved higher by 4.9% in pre-market trading after the company reported Q4 results.

Recap: Cantel Medical Q4 Earnings

LITTLE FALLS, N.J., Sept. 17, 2020 /PRNewswire/ -- Cantel Medical Corp.

Cantel Medical Reports Financial Results for its Fourth Quarter Fiscal Year 2020

Earnings Preview: Cantel Medical (CMD) Q4 Earnings Expected to Decline

LITTLE FALLS, N.J., Sept. 3, 2020 /PRNewswire/ -- CANTEL MEDICAL CORP.

Cantel Medical Corp. to Hold Conference Call to Discuss Results for its Fourth Quarter Ended July 31, 2020

LITTLE FALLS, N.J., Aug. 6, 2020 /PRNewswire/ -- CANTEL MEDICAL CORP.

Cantel Pre-Announces Estimated Revenue for the 4th Quarter

LITTLE FALLS, N.J., Aug. 3, 2020 /PRNewswire/ -- CANTEL MEDICAL CORP.

News for Cantel Medical Stock (CMD)